TCT 2021: Is Idecabtagene Vicleucel Safe for Elderly Patients With Resistant Myeloma?
Posted: Friday, February 19, 2021
Jesus G. Berdeja, MD, of the Sarah Cannon Research Institute, Nashville, and colleagues evaluated the safety and efficacy of idecabtagene vicleucel (formerly known as bb2121) in elderly patients with relapsed and refractory multiple myeloma. At the 2021 Transplantation & Cellular Therapy Meetings (TCT), these researchers reported their subgroup analysis of the KarMMa trial, indicating that this immunotherapy appears to be safe and active in these individuals (Abstract 486).
“These results demonstrate deep and durable responses with idecabtagene vicleucel treatment together with a manageable safety profile in triple-class–exposed patients with relapsed and refractory multiple myeloma aged [greater than 65 years and 70 years],” the investigators concluded.
The KarMMa trial enrolled 128 patients with relapsed and refractory multiple myeloma. A total of 35% of patients were aged 65 and older, and 16% were aged 70 and older at diagnosis. In the 65-and-older group, the median age of patients at diagnosis was 69, whereas the median age at diagnosis in the 70-and-older group was 73. Participants were required to have had three or more prior lines of therapy, which included a proteasome inhibitor, an anti-CD38 antibody, and an immunomodulatory drug, and were refractory to their last treatment. After 3 days of fludarabine and lymphodepletion with cyclophosphamide followed by 2 days of rest, individuals were administered idecabtagene vicleucel at target doses of 150, 300, or 450 × 106 chimeric antigen receptor–positive T cells.
The median progression free survival for the 65-and-older group, the 70-and-older group, and all treated patients was 8.6, 10.2, and 8.8 months, respectively. The median duration of response in the 65-and-older (10.9 months) and 70-and-older (11.0 months) groups was longer than in all patients treated with idecabtagene vicleucel (10.7 months).
Disclosure: For full disclosures of the study authors, visit tct.confex.com.
